← ResMed overview

ResMed vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ResMed Inc (RMD)

Q3 2026
▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

  • Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.

    Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.

  • Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.

    The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.

  • Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.

    Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.

  • Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.

    These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

August 2026
▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

  • Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.

    Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.

  • Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.

    The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.

  • Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.

    Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.

  • Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.

    These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Latest
▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

  • Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.

    Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.

  • Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.

    The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.

  • Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.

    Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.

  • Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.

    These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Integer Holdings Corp (ITGR)

Q3 2026
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

July 2026
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

Latest
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

© 2026 MarketIVWhy